Literature DB >> 9758359

Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.

K Washington1, A Chiappori, K Hamilton, Y Shyr, C Blanke, D Johnson, J Sawyers, D Beauchamp.   

Abstract

Loss of expression and function of the E-cadherin/catenin membrane complex can result in loss of cell adhesion and contribute to invasive or metastatic potential in carcinomas. The aim of this study was to examine the expression of alpha- and beta-catenin and E-cadherin in Barrett's esophagus with and without dysplasia and in esophageal adenocarcinomas and to identify any relationship with tumor growth pattern and clinical outcome. Immunoperoxidase staining for alpha- and beta-catenin and E-cadherin was performed on specimens of Barrett's esophagus with and without dysplasia and on 54 esophageal adenocarcinoma specimens. Membranous staining for all of the components was seen in normal gastric and esophageal mucosa. Abnormal expression of beta-catenin, alpha-catenin, and E-cadherin was significantly associated with higher degrees of dysplasia in Barrett's esophagus. Fourteen of 16 cases of high grade dysplasia and 7 of 7 cases of intramucosal carcinoma showed abnormal expression of beta-catenin, compared with 3 of 6 cases indefinite for dysplasia and 11 of 17 cases with low grade dysplasia (P = 0.022). Similar results were seen for expression of alpha-catenin (P < .01) and E-cadherin (P = .049). In esophageal adenocarcinomas, preserved expression of these proteins occurred more frequently in well-differentiated tumors; abnormal expression was more common in diffusely infiltrative poorly differentiated tumors that did not form glands. Focal nuclear staining for beta-catenin was present in two high-grade dysplasias, two intramucosal carcinomas, and five adenocarcinomas. No survival advantage was demonstrated for patients whose tumors retained expression of these cell adhesion components. In conclusion, abnormal expression of the E-cadherin/catenin membrane complex is common in esophageal adenocarcinoma and occurs early in the dysplasia/carcinoma sequence in Barrett's esophagus, indicating that disturbances in this cell adhesion complex might be important in tumorigenesis and tumor progression in this disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758359

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  19 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katherine S Garman; Roy C Orlando; Xiaoxin Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

Review 3.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

4.  Analysis of beta-catenin mutations and alpha-, beta-, and gamma-catenin expression in normal and neoplastic human pituitary tissues.

Authors:  V Tziortzioti; K H Ruebel; T Kuroki; L Jin; B W Scheithauer; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Management of Barrett's esophageal carcinoma.

Authors:  Tatsuya Miyazaki; Takanori Inose; Naritaka Tanaka; Takehiko Yokobori; Shigemasa Suzuki; Daigo Ozawa; Makoto Sohda; Masanobu Nakajima; Minoru Fukuchi; Hiroyuki Kato; Hiroyuki Kuwano
Journal:  Surg Today       Date:  2013-01-03       Impact factor: 2.549

Review 6.  Esophageal adenocarcinoma arising in Barrett esophagus.

Authors:  Hui Ying Zhang; Stuart Jon Spechler; Rhonda F Souza
Journal:  Cancer Lett       Date:  2008-08-13       Impact factor: 8.679

Review 7.  Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis.

Authors:  Jacqueline M Benjamin; W James Nelson
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

8.  Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma.

Authors:  Ali H Zaidi; Vanathi Gopalakrishnan; Pashtoon M Kasi; Xuemei Zeng; Usha Malhotra; Jeya Balasubramanian; Shyam Visweswaran; Mai Sun; Melanie S Flint; Jon M Davison; Brian L Hood; Thomas P Conrads; Jacques J Bergman; William L Bigbee; Blair A Jobe
Journal:  Cancer       Date:  2014-08-05       Impact factor: 6.860

Review 9.  Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract.

Authors:  Ammar Natalwala; Robert Spychal; Chris Tselepis
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

10.  Esophagectomy for adenocarcinoma in patients 45 years of age and younger.

Authors:  J Scott Bolton; T T Wu; C J Yeo; J L Cameron; R F Heitmiller
Journal:  J Gastrointest Surg       Date:  2001 Nov-Dec       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.